Aster DM Q3 FY26 results: revenue up, PAT flat; QCIL merger moves ahead
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 2.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q3 FY26 consolidated revenue rose 12.9% YoY to about Rs 1,186 cr; PAT dipped to Rs 58.65 cr from Rs 64.39 cr. Nine-month revenue grew to Rs 3,461 cr and PAT to Rs 274 cr. Board approved ESOP Scheme 2026, converted Rs 129.35 cr loan into equity in a hospital unit, and noted NCLT approval for shareholder and creditor meetings on the Quality Care India merger, to be held Feb 27 to Mar 13. Labour Codes impact of about Rs 27.86 cr shown as exceptional. Auditor Deloitte gave unmodified opinion.
Steady revenue growth; PAT hit by Labour Codes and merger costs; QCIL merger approval is a key positive catalyst.